21
TITLE: Comparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitnib for advanced renal cell carcinoma in the UK Perspective
AUTHORS: De Mello, RA; Ayoub, E; Castelo Branco, P; Zia, VAD; Savio, A; Pozza, DH ; Tadokoro, H; Teich, N;
PUBLISHED: 2020, SOURCE: Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO) in JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 38, ISSUE: 6
INDEXED IN: WOS CrossRef: 2
IN MY: ORCID
22
TITLE: The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer
AUTHORS: Ramon Andrade De Mello; Nathalia Moises Neves; Giovanna Araujo Amaral; Estela Gudin Lippo; Pedro Castelo Branco; Daniel Humberto Pozza ; Carla Chizuru Tajima; Georgios Antoniou;
PUBLISHED: 2020, SOURCE: JOURNAL OF CLINICAL MEDICINE, VOLUME: 9, ISSUE: 6
INDEXED IN: WOS CrossRef: 12
IN MY: ORCID
23
TITLE: DNA hypermethylation within TERT promoter upregulates TERT expression in cancer
AUTHORS: Lee, DD; Leao, R; Komosa, M; Gallo, M; Zhang, CH; Lipman, T; Remke, M; Heidari, A; Nunes, NM; Apolonio, JD; Price, AJ; De Mello, RA; Dias, JS; Huntsman, D; Hermanns, T; Wild, PJ; Vanner, R; Zadeh, G; Karamchandani, J; Das, S; Taylor, MD; Hawkins, CE; Wasserman, JD; Figueiredo, A; Hamilton, RJ; Minden, MD; Wani, K; Diplas, B; Yan, H; Aldape, K; Akbari, MR; Danesh, A; Pugh, TJ; Dirks, PB; Castelo Branco, P; Tabori, U; ...More
PUBLISHED: 2019, SOURCE: JOURNAL OF CLINICAL INVESTIGATION, VOLUME: 129, ISSUE: 1
INDEXED IN: Scopus WOS CrossRef: 108
IN MY: ORCID
24
TITLE: Hot topics in epigenetic regulation of cancer self-renewal for pancreatic tumors: future trends
AUTHORS: De Mello, RA; Faleiro, I; Apolonio, JD; Tabori, U; Price, AJ; Roberto, VP; Castelo Branco, P;
PUBLISHED: 2019, SOURCE: FUTURE ONCOLOGY, VOLUME: 15, ISSUE: 7
INDEXED IN: WOS CrossRef: 2
IN MY: ORCID
25
TITLE: PALOMA-3 clinical trial: is there a significant benefit in overall survival for breast cancer? Is it worth it?
AUTHORS: Adashek, JJ; Aguiar, PN; Castelo Branco, P; Lopes, GL; de Mello, RA;
PUBLISHED: 2019, SOURCE: FUTURE ONCOLOGY, VOLUME: 15, ISSUE: 13
INDEXED IN: Scopus WOS CrossRef: 5
IN MY: ORCID
26
TITLE: Cellular Interactions in the Tumor Microenvironment: The Role of Secretome
AUTHORS: da Cunha, BR; Domingos, C; Stefanini, ACB; Henrique, T; Polachini, GM; Castelo Branco, P; Tajara, EH;
PUBLISHED: 2019, SOURCE: JOURNAL OF CANCER, VOLUME: 10, ISSUE: 19
INDEXED IN: Scopus WOS CrossRef: 91
IN MY: ORCID
27
TITLE: Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: A network meta-analysis
AUTHORS: De Mello, RA; Escriu, C; Castelo Branco, P; Cabral, PL; Mountzios, G; Lopes, GL; Madureira, P;
PUBLISHED: 2018, SOURCE: Oncotarget, VOLUME: 9, ISSUE: 14
INDEXED IN: Scopus CrossRef: 6
IN MY: ORCID
28
TITLE: MetaLanc9 as a novel biomarker for non-small cell lung cancer: promising treatments via a PGK1-activated AKT/mTOR pathway
AUTHORS: Ramon Andrade De Mello; Pedro Nazareth Aguiar; Hakaru Tadokoro; Tallita Meciany Farias Vieira; Pedro Castelo Branco; Gilberto de Lima Lopes; Daniel Humberto Pozza ;
PUBLISHED: 2018, SOURCE: JOURNAL OF THORACIC DISEASE, VOLUME: 10, ISSUE: S16
INDEXED IN: WOS CrossRef: 8
IN MY: ORCID
29
TITLE: What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies?
AUTHORS: Ramon Andrade De Mello; Luis Castelo-Branco; Pedro Castelo-Branco; Daniel Humberto Pozza ; Louis Vermeulen; Sofia Palacio; Matthew Salzberg; Craig C Lockhart;
PUBLISHED: 2018, SOURCE: American Society of Clinical Oncology Educational Book, ISSUE: 38
INDEXED IN: CrossRef: 3
IN MY: ORCID
30
TITLE: Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer
AUTHORS: Ricardo Leão; Joana Dias Apolónio; Donghyun Lee; Arnaldo Figueiredo; Uri Tabori; Pedro Castelo-Branco;
PUBLISHED: 2018, SOURCE: Journal of Biomedical Science, VOLUME: 25, ISSUE: 1
INDEXED IN: CrossRef: 161
IN MY: ORCID
Page 3 of 6. Total results: 51.